Matthew Pauls

Mr. Pauls has served as Savara’s Chief Executive Officer since December 2020, Chair of the Board of Directors since September 2020, and the company’s Interim Chief Executive Officer from September 2020 to December 2020. He has been a member of Savara’s Board of Directors since April 2017 and was Chair of the Mast Therapeutics (NYSE: MAST) Board of Directors (Savara closed a reverse merger with Mast Therapeutics in April 2017). Previously, Mr. Pauls was the Founder of Spartan Biopharma Insights, LLC, where he provided strategic advice to institutional investors and company management teams on investment thesis assessment, capitalization strategy, mergers and acquisitions, clinical execution, and commercialization. He also previously served on the Zyla Life Sciences Board of Directors, which merged with Assertio Therapeutics in 2020. Prior to that, Mr. Pauls was President and Chief Executive Officer and, from October 2015 to November 2019, a member of the Strongbridge Biopharma plc Board of Directors. Strongbridge was a publicly-traded rare-disease focused biopharmaceutical company that he took public via IPO on the NASDAQ. Prior to Strongbridge, Mr. Pauls was Chief Commercial Officer of Insmed, Inc., a publicly-traded global biopharmaceutical company focused on rare respiratory diseases. Prior to Insmed, he worked at Shire Pharmaceuticals most recently as Senior Vice President, Head of Global Commercial Operations. Earlier in his career, Mr. Pauls held senior U.S. and global commercial leadership positions at Bristol-Myers Squibb and Johnson & Johnson. Mr. Pauls holds B.S. and M.B.A. degrees from Central Michigan University and a J.D. from Michigan State University College of Law.